Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab and Anlotinib with Chemotherapy in Early-stage TNBC
NCT07896668Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 2 trial of pucotenlimab, anlotinib in triple-negative breast cancer (TNBC), sponsored by Zhejiang Cancer Hospital. Started Sep 2025; status: recruiting.
02
Drugs
pucotenlimabanlotinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07896668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07896668.